Skip to main content
Log in

Sertraline

Chronopharmacokinetics and the Effect of Coadministration with Food

  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Two nonblinded single-dose randomised 3-way crossover studies were conducted in healthy male volunteers to determine the effect of the time of administration (morning vs evening) and the effect of food on the pharmacokinetics of sertraline tablets.

There were no significant treatment effects on the mean area under the plasma concentration-time curve (AUC), mean peak plasma sertraline concentration (Cmax), mean time to reach Cmax (tmax), mean terminal elimination half-life, or the mean elimination rate constant in either study. The results of these 2 studies show that the bioavailability and elimination of sertraline tablets are not influenced by the time of administration or administration with or without food. Thus, sertraline tablets offer the flexibility of morning or evening administration, to patients in the fasting or nonfasting state.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984; 6: 592–9

    PubMed  CAS  Google Scholar 

  2. Melander A, Lalka D, McLean A. Influence of food on the presystemic metabolism of drugs. Pharmacol Ther 1988; 38: 253–67

    Article  PubMed  CAS  Google Scholar 

  3. Fujimura A, Kajiyama H, Kumagai Y, et al. Chronopharmacokinetic studies of pranoprofen and procainamide. J Clin Pharmacol 1989; 29: 786–90

    PubMed  CAS  Google Scholar 

  4. Physicians’ Desk Reference. 48th ed. Montvale, NJ: Medical Economics Data Production Company, 1994

  5. Greb WH, Brett MA, Buscher G, et al. Absorption of paroxetine under various dietary conditions and following antacid intake. Acta Psychiatr Scand Suppl. 1989; 350: 99–101

    Article  PubMed  CAS  Google Scholar 

  6. Benfield P, Ward A. Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32: 313–34

    Article  PubMed  CAS  Google Scholar 

  7. Wheeler SC, Vlasses PH, Dobinska MR, et al. Plasma fluvoxamine levels in fasted and fed subjects. J Clin Pharmacol 1985; 25: 463

    Google Scholar 

  8. Lemberger L, Bergstrom RF, Wolen RL, et al. Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry 1985; 46 (3 sec 2): 14–9

    PubMed  CAS  Google Scholar 

  9. Tremaine LM, Joerg EA. Automated gas chromatographicelectron-capture assay for the selective serotonin uptake blocker sertraline. J Chromatogr 1989; 496: 423–9

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ronfeld, R.A., Wilner, K.D. & Baris, B.A. Sertraline. Clin-Pharmacokinet 32 (Suppl 1), 50–55 (1997). https://doi.org/10.2165/00003088-199700321-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199700321-00008

Keywords

Navigation